AEYE Diagnostic Screening
AEYE Diagnostic Screening (AEYE-DS) utilizes Artificial Intelligence (AI) technology to diagnose diabetic retinopathy from retinal images.
First to be proven accurate on both a desktop camera and a portable handheld camera
AEYE with TOPCON
CAUTION: Federal (US) law restricts this device to investigational use only.
NOT SOLD IN THE US
Proven accurate in a prospecitve clinical trial
The Only Practical Solution
The exam takes under 2 minutes for most patients and rarely requires dilation
handheld & desktop
Closes Care Gaps
Enables point-of-care screening instead of referring to a specialist
HEDIS Quality Measure
people with diabetes in the US and 422M worldwide are at risk of sight-threatening diabetic retinopathy.
of people over 40 with diabetes will develop diabetic retinopathy.
Why it matters
Screening Prevents Blindness
Accessible and affordable screening for diabetic retinopathy is vital to help ensure patients with diabetes receive sight-saving treatment.
Only 15% to 50%
of patients with diabetes in the US adhere to the recommended screening.
Closing care gaps
Replacing specialist screening with AI diagnosis
Using AI technology, primary care physicians can screen for diabetic retinopathy on the spot, replacing specialist referrals and closing the diabetic retinopathy care gap
Requires only one image per eye; rarely requires dilation
Best-in-class efficacy proven in a pivotal prospective FDA study
Simple to operate
Screening, taking only two minutes for most patients, can be done by any healthcare staff
Dedicated CPT code 92229
Closes Care Gaps
Closes the diabetic eye exam care gap for HEDIS/Star quality measures
See what people are saying about us
The time has finally come for autonomous screening technology to exceed the efficacy of the human expert. The implications are that it can be practical for deployment on the front lines of population health – the primary care offices, where over 99% imageability and single image diagnostic acquisition are tantamount to market success
MD, MPH, CEO at Eyenovia. Professor of Ophthalmology at UCSF & Mt. Sinai